1. Home
  2. MPLT vs ASTH Comparison

MPLT vs ASTH Comparison

Compare MPLT & ASTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

N/A

Current Price

$6.99

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Logo Astrana Health Inc.

ASTH

Astrana Health Inc.

N/A

Current Price

$36.36

Market Cap

1.9B

ML Signal

N/A

Company Overview

Basic Information
Metric
MPLT
ASTH
Founded
2018
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
2025
2015

Fundamental Metrics

Financial Performance
Metric
MPLT
ASTH
Price
$6.99
$36.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
11
Target Price
$26.54
★ $51.67
AVG Volume (30 Days)
★ 330.9K
251.3K
Earning Date
12-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 82.39
N/A
EPS
N/A
★ 0.69
Revenue
N/A
★ $519,907,752.00
Revenue This Year
N/A
$25.15
Revenue Next Year
N/A
$10.10
P/E Ratio
★ N/A
$53.51
Revenue Growth
N/A
★ 45.90
52 Week Low
$6.82
$18.08
52 Week High
$40.43
$51.60

Technical Indicators

Market Signals
Indicator
MPLT
ASTH
Relative Strength Index (RSI) 28.92 47.30
Support Level N/A $36.55
Resistance Level $8.58 $40.05
Average True Range (ATR) 0.54 1.30
MACD 0.06 -0.09
Stochastic Oscillator 11.29 24.92

Price Performance

Historical Comparison
MPLT
ASTH

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

About ASTH Astrana Health Inc.

Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.

Share on Social Networks: